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py.1-4 Heart disease has become a major cause of late
morbidity and mortality in these groups of patients.5-8
The effects of mediastinal radiation therapy on the heart
include pericardial disease, myocardial fibrosis, valvular
heart disease, coronary artery disease, and conduction
disturbances.9 A relatively small number of cases of
coronary artery bypass grafting (CABG) in patients with
previous mediastinal radiation therapy have been report-
ed.10-15 This is a single-center study of coronary revas-
cularization in patients with previous mediastinal radia-
tion therapy over a 21-year period to establish early and
late outcomes and identify special features of this dis-
ease as they relate to surgical management. 
Patients and methods 
At the Mayo Clinic, from January 1976 through December
1996, patients who had a CABG procedure were matched
A n increasing number of patients with malignant neo-plasm treated with irradiation survive long term after
treatment. In particular, there are an increasing number
of long-term survivors of Hodgkin’s disease and breast
cancer who have undergone mediastinal radiation thera-
Objectives: Our objectives were to characterize the outcome of coronary
artery bypass grafting in patients with previous mediastinal radiation
therapy and to identify special features of this condition that relate to
surgical management. Patients and methods: We conducted a retrospective
review of 47 patients (28 women, 19 men) with a mean age of 63.5 ± 12.8
years (range 31.0-82.9 years) from 1976 through December 1996 under-
going coronary artery bypass graft after mediastinal radiation therapy.
Results: The mean interval between mediastinal radiation therapy and
coronary artery bypass grafting was 15.1 ± 9.8 years (range 1.1-37.8
years). In the 44 patients with isolated coronary surgery, operative mor-
tality was 3 patients (6.8%). Sternal wound infection occurred in 3
patients (6.8%). Actuarial survival at 1 and 5 years was 87.2% ± 4.9%
and 71.6% ± 7.1%, respectively. Total follow-up was 293.7 patient-years
(mean 6.2 ± 5.1 years). There were 17 late deaths (malignancy, n = 7;
heart failure, n = 6; stroke, n = 1; other noncardiac causes, n = 2; and
sudden death, n = 1). Twelve of 43 discharged patients had the develop-
ment of valvular disease demonstrated by follow-up echocardiography.
Conclusions: The early results of coronary artery bypass grafting for the
treatment of ischemic heart disease after mediastinal radiation therapy
are good. Late survival, however, is limited by malignancy, either recur-
rent or new, and the development of heart failure. Inasmuch as 25 other
patients after radiation therapy required concomitant valve surgery and
12 of 43 (28%) discharged patients had later development of valvular
disease, with 2 requiring reoperation, careful assessment of any valvular
lesion is important during the initial coronary artery bypass grafting.
Careful follow-up, including regular echocardiographic screening, is
recommended in this patient population. (J Thorac Cardiovasc Surg
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with patients with malignant neoplasms who might have been
treated by mediastinal radiation therapy. Those malignant
neoplasms include breast cancer, lymphoma, lung cancer,
esophageal cancer, thymoma, and germ cell tumors of the
mediastinum.16 A total of 72 patients were identified. Cardiac
surgical procedures performed are detailed in Table I.
Twenty-five patients who had combined CABG and valve
surgery were excluded from this analysis. Accordingly, 47
patients were evaluated in this study. A retrospective review
of operative notes, anesthesia records, clinical case histories,
and laboratory investigations including electrocardiography,
echocardiography, cardiac catheterization data and radiation
oncology records was done. Follow-up data were collected by
clinic records of subsequent outpatient visits and correspon-
dence with patients and referring physicians, focusing on
functional and echocardiographic status as well as the state of
the malignant disease. A total of 264 clinical, hemodynamic,
electrocardiographic, and echocardiographic variables in
each patient were entered into a computerized database and
analyzed. More than 6 months’ follow-up data were complet-
ed in all patients. Demographic and cardiac data of the 47
patients in this study are detailed in Table II. Of note, 60%
were female and 32% of patients had left main disease. 
Preoperative risk factors and comorbidities are detailed in
Table III. Of note, esophageal stricture and pulmonary fibro-
sis induced by mediastinal radiation therapy were observed in
3 (6%) and 11 (23%) patients, respectively. Thirty-two per-
cent of the patients had pulmonary parenchymal disease,
either chronic obstructive pulmonary disease or pulmonary
fibrosis (or a combination of the two). Carotid disease,
defined as more than 50% stenosis, documented by carotid
ultrasound or angiography, was present in 11 patients (23%).
The indications for mediastinal radiation therapy were breast
cancer in 26 patients (55%), Hodgkin’s lymphoma in 10
patients (21%), non-Hodgkin’s lymphoma in 8 patients
(17%), and lung cancer in 3 patients (6%). Radiation dosage
was available in 26 of 47 patients (55%). The mean dose of
radiation was 57.3 ± 17.7 Gy. The interval between the end of
radiation therapy and CABG was 15.1 ± 9.8 years (range 1.1-
37.8 years). Nine patients had chemotherapy concomitant
with mediastinal radiation therapy. 
Other cardiac lesions were assessed by either cardiac
catheterization or echocardiography. Three of the 47 patients
with moderate mitral regurgitation and 1 patient with moderate
tricuspid regurgitation underwent CABG alone. No other
patient had significant aortic, mitral, or tricuspid valve disease.
The mean preoperative ejection fraction was 54.5% ± 12.4%. 
Statistical methods. Survival, survival free of cardiac
events, and reoperation were estimated as a function of time
since surgery by means of the Kaplan-Meier method. Survival
curves were compared by means of the log-rank test. Patient
characteristics between groups were compared by means of c 2
tests or Fisher’s exact tests for nominal variables, with 2-sam-
ple t tests or Wilcoxon rank-sum tests for continuous variables
and with Wilcoxon rank-sum tests for ordinal variables.
Results
The number of CABG procedures after mediastinal
radiation therapy has increased over time at our institu-
Table I. Cardiac surgical procedures performed in 72
patients after mediastinal radiation therapy
Surgical 
procedures No.
Study group 47
CABG 44
CABG + pericardiectomy 2
CABG + LV aneurysmectomy 1
Excluded patients 25
CABG + single valve surgery 19
CABG + multiple valve surgery 6
Total 72
CABG, Coronary artery bypass grafting; LV, left ventricular.
Table II. Demographic and cardiac data (47 patients)
Variable No. (n = 47) %
Male sex 19 40
Age (y) 63.5 ± 12.8
NYHA class III or IV 43 92
History of stroke 3 6
Previous heart surgery 1 2
History of MI 27 57
History of PTCA 7 15
History of arrhythmia 5 10
One-vessel disease 3 6
Two-vessel disease 12 26
Three-vessel disease 32 68
Left main disease 15 32
NYHA, New York Heart Association; MI, myocardial infarction; PTCA, per-
cutaneous transluminal coronary angioplasty. 
Table III. Preoperative risk factors for coronary
artery disease and comorbidities
Variable No. (n = 47) %
Risk factors
Smoking history 15 32
Hypertension 22 47
Hyperlipidemia 15 32
Diabetes mellitus 14 30
Family history 16 34
Comorbidity
Peripheral vascular disease 8 17
Carotid disease 11 23
Esophageal stricture 3 6
Pulmonary parenchymal disease 15 32
COPD 4
Pulmonary fibrosis 3
Both 8
COPD, Chronic obstructive pulmonary disease.
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tion (9 cases from 1976 to 1982, 15 cases from 1983 to
1989, and 20 cases from 1990 to 1996). The surgical
procedures are detailed in Table IV. The mean number
of distal anastomoses was 2.9 ± 0.9. Three patients had
procedures in addition to CABG: coronary endarterec-
tomy (n = 2), pericardiectomy (n = 2), and left ventric-
ular aneurysmectomy (n = 1). One patient had mini-
mally invasive CABG without cardiopulmonary
bypass. Of note, the left internal thoracic artery (LITA)
was used to graft the left anterior descending (LAD)
artery in 32% of patients. Use of the LITA graft was
broken down into 3 time periods according to the year
of operation, and the frequency increased over the peri-
od of the study (Fig 1). In the most recent time period
(1990-1996) the LITA was used to graft the LAD in
50% of patients. In 20% of cases in which the saphe-
nous vein was used as a conduit to the LAD, the sur-
geon commented on the operation report that the LITA
was involved in areas of mediastinal fibrosis.
Perioperative mortality and morbidity are shown in
Table V. Overall perioperative mortality was 4 patients
(8.5%). One of these 4 patients had CABG plus peri-
cardiectomy. This patient was a 74-year-old man with
diabetes in whom mediastinitis developed; he subse-
quently died of infective endocarditis on postoperative
day 15. Operative mortality, therefore, for the patients
with isolated CABG (n = 44) was 3 patients (6.8%).
The first of these 3 patients, a 54-year-old woman, was
discharged on postoperative day 8 and died of an
apparent myocardial infarction 6 days later. The second
Fig 1. The relative percentages of patients receiving a saphenous vein graft (SVG), a left internal thoracic artery
(LITA) graft, or no graft to the LAD over 3 time frames.
Table IV. Surgical procedures
Variable No. (n = 47) %
Graft to LAD
LITA 14 30
SVG 26 55
LITA and SVG 1 2
No graft to LAD 6 13
CABG + coronary endarterectomy 2
CABG + pericardiectomy 2
CABG + LV aneurysmectomy 1
No. of distal anastomoses 2.9 ± 0.9
CPB time (min) 99.6 ± 34.9
Aortic crossclamp time (min) 50.9 ± 20.4
LAD, Left anterior descending; LITA, left internal thoracic artery; SVG, saphe-
nous vein graft; CABG, coronary artery bypass graft; LV, left ventricular; CPB,
cardiopulmonary bypass.
Table V. Perioperative mortality and morbidity
Variable No. (n = 47) %
Mortality (overall) 4 8.5
Mortality (CABG alone) (n = 44) 3 6.8
Mediastinal re-exploration for bleeding 2 4.3
Prolonged ventilation (>72 h) 4 8.5
Use of IABP 2 4.3
Deep sternal infection 3 6.8
Sternal malunion 1 2.1
Renal insufficiency (creatine > 3.0 mg/dL) 1 2.1
GI perforation 1 2.1
Infective endocarditis 1 2.1
ICU stay (days) (mean) 2.35 ± 1.3
Hospital stay (days) (mean) 11.5 ± 11.3
CABG, Coronary artery bypass graft; IABP, intra-aortic balloon pump; GI,
gastrointestinal; ICU, intensive care unit.
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patient, a 59-year-old man with a preoperative ejection
fraction of 36% and an evolving myocardial infarction,
had an emergency operation and died on the first post-
operative day. The third patient was an 82-year-old
woman who died on postoperative day 36 of heart fail-
ure after needing prolonged respiratory support and tra-
cheostomy. She had also had a gastrointestinal perfora-
tion with abdominal exploration. Four patients, in total,
required prolonged ventilatory support (>72 hours).
Three patients had a deep sternal wound infection and
1 patient had sternal malunion with no evidence of
infection. The LITA was not used in any of the 3
patients with mediastinitis. 
Total follow-up was 293.7 patient-years with a mean
of 6.2 ± 5.1 years. Follow-up New York Heart
Association (NYHA) class was I in 51% (n = 22), II in
26% (n = 11), III in 14% (n = 6), and IV in 9% (n = 4)
of patients. Seventeen late deaths occurred. The two
major causes of late death were malignancy, either
recurrent (n = 2) or new (n = 5), and heart failure (n =
6). Other causes of late death were stroke (n = 1), sud-
den death (n = 1), and other noncardiac causes (n = 2).
Actuarial survivals at 1 year and 5 years were 87.2% ±
4.9% and 72.6% ± 7.1%, respectively (Fig 2). Five
patients required 6 late reoperations (CABG, n = 3; aor-
tic valve replacement plus CABG, n = 1; mitral valve
repair, n = 1; and heart transplantation, n = 1). Survival
free of cardiac-related death, open cardiac reoperation,
and redo CABG at 5 years was 88.0% ± 5.2%, 78.3% ±
7.3%, and 93.5% ± 4.4%, respectively (Figs 2 and 3).
Table VI shows a comparison of LITA and saphenous
vein usage as an LAD conduit in terms of survival free
from death, cardiac death, cardiac reoperation, and
CABG reoperation at 3 years. The small numbers of
patients prevent any later analysis. The mean interval
between the original CABG and the 6 late cardiac pro-
cedures was 4.6 ± 2.5 years (2.5-8.6 years). 
Follow-up valve assessment by echocardiography
was available in only 21 patients (45%) with a mean
follow-up of 5.9 ± 4.7 years. Twelve of these 21
patients were noted to have significant valvular disease
(mitral plus tricuspid valve disease, n = 4; aortic plus
mitral stenosis, n = 5; aortic stenosis plus regurgitation,
n = 2; mild aortic stenosis, n = 1). Two of these patients
required reoperation for this valvular disease. Another
2 of these patients died of congestive heart failure. Six
of the 10 patients who were in NYHA class III or IV at
follow-up had significant valvular disease. 
Discussion
Over the time frame of this study, an increasing num-
ber of patients required CABG operations after previ-
ous mediastinal radiation therapy. Although the number
of long-term survivors after radiation therapy for cer-
tain malignant neoplasms is increasing, it can be hoped
that the frequency of mediastinal complications will
diminish with improved radiation therapy techniques.
In particular, the use of more frequent but lower
dosages of radiation to multiple fields and customized
computed tomographic blocking have resulted in more
focused and homogeneous dosing of radiation.8,17,18
The spectrum of mediastinal radiation injury is broad,
extending from minor fibrosis with little or no structur-
al effects to heavy scarring and fusion of mediastinal
Fig 2. Freedom from cardiac death and death from all causes in 47 patients undergoing coronary artery bypass
grafting (CABG) after mediastinal radiation therapy.
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structures with extensive pericardial, myocardial, vas-
cular, and valvular damage.8 Radiation injury to the
aortic arch and great vessels may also occur.19 The low
incidence of classic risk factors for coronary artery dis-
ease in this study, such as hyperlipidemia and a history
of smoking, support the role of mediastinal radiation
therapy in the development of coronary disease in these
patients. Careful preoperative assessment of patients
for comorbidities resulting from previous radiation
therapy may be helpful in risk assessment for any indi-
vidual patient. The frequency of carotid stenosis, pul-
monary dysfunction, and pericardial constriction indi-
cates the need for preoperative carotid ultrasonography,
pulmonary function testing, and echocardiography.19,20
Computed tomography of the chest may also be useful
in delineating the extent of mediastinal changes.
Echocardiography will also yield additional important
information on right and left ventricular function, as
well as on valvular function.19 The frequent presenta-
tion of mixed ischemic and valvular heart disease in
this patient population mandates careful preoperative
echocardiography. This study suggests that valvular
disease in this patient population is progressive, so that
concomitant valve surgery with CABG should be care-
fully considered. The progression in valvular heart dis-
ease is based on (1) the need for valvular reoperation in
2 patients (neither of whom was in the group of 4
patients with moderate valvular disease at the time of
CABG alone); (2) valvular heart disease being impli-
cated in 3 of the 6 late deaths from heart failure and 6
of 10 patients who were in NYHA class II or IV at fol-
low-up; and (3) echocardiographic follow-up. This pro-
gression of valvular disease may be underestimated,
because echocardiographic follow-up was available in
only 21 of the 43 surviving patients, 12 of whom had
significant valvular disease. Pathologic assessment of
the resected heart valves in 25 of the original 72
patients showed leaflet fibrosis and fibrous shortening
of the chordae tendineae in all but 1 mitral valve, con-
sistent with radiation-induced disease. With respect to
the aortic valve, one third of valves had diffuse leaflet
fibrosis and retraction typical of radiation-induced
injury. The other two thirds showed overlapping age-
related degenerative (senile) calcification and varying
degrees of fibrosis. Radiation-induced injury appeared
to be the main factor for the development of mitral
valve disease and at least a contributing factor for the
development of aortic valve disease. At this time, we
cannot comment on the applicability of valve repair
versus replacement, because our analysis of valvular
heart disease is not yet complete. 
The use of the LITA as an LAD graft in 32% of
patients in this study is similar to the percentage in pre-
Fig 3. Freedom from redo coronary artery bypass grafting (CABG) and all cardiac reoperations in 47 patients
undergoing CABG after mediastinal radiation therapy.
Table VI. Comparison of LITA and SV as an LAD
graft
Survival free from the following 
variables at 3 years (%)
Variable LITA (n = 14) SV (n = 25) P value
Death 93 ± 6 76 ± 9 .87
Cardiac death 100 ± 0 89 ± 6 .63
Cardiac reoperation 91 ± 9 100 ± 0 .27
Redo CABG 100 ± 0 100 ± 0 .44
LITA, Left internal thoracic artery; SV, saphenous vein; LAD, left anterior
descending; CABG, coronary artery bypass graft.
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vious studies.11,15 The use of the LITA has increased
over the time frame of the study to 50% in the most
recent period. The low use of the LITA in the earlier
time frames of the study may reflect an era before the
full value of the LITA was realized. In addition, the
decision not to use the LITA might have been influ-
enced by the concern about a possible increased inci-
dence of mediastinitis after the operation. However,
although the incidence of mediastinitis appeared high
in this series (3/47), in none of these cases was the
LITA used. The increased incidence of mediastinitis is
likely due to the low-grade chronic inflammation of
radiation therapy compromising local blood supply to
the sternum and soft tissues. It is easy to speculate that
the LITA surrounded by the mediastinal fibrotic
process is likely to be affected by radiation-induced
arteritis. This raises the question of long-term patency
of these LITA grafts. In the present study, unfortunate-
ly, pathologic assessment of LITA grafts is not avail-
able. Late occlusion of a LITA graft to the LAD has
been reported in a patient who had CABG after medi-
astinal radiation therapy.21 In 20% of cases in which the
saphenous vein was used to bypass the LAD, the sur-
geon commented on the involvement of the LITA in the
mediastinal fibrotic process, obviating its use.
Preoperative LITA angiography clearly is desirable but
was available in only 1 patient in the study. A normal
preoperative angiogram of the LITA would support
LITA use in this population. Whether the LITA is the
conduit of choice because of its well-known advan-
tages22-25 is uncertain in this population, not only
because of concerns regarding its involvement by radi-
ation, but also because its positive long-term impact is
less in this patient population, who has significant late
attrition resulting from neoplasm, valvular heart dis-
ease, and heart failure. The comparison of survival free
of variables at 3 years between LITA and saphenous
vein usage for the LAD conduit (Table VI) and the 5-
year survival free of redo CABG of 93.5% (Fig 3) sup-
port this contention, at least in the 3- to 5-year time
frame. The questionable quality of the LITA graft after
mediastinal radiation therapy, the increased risk of
mediastinal wound complications, and the reduced
impact on 5-year survival raises the legitimate question
of whether an alternative arterial graft that is not affect-
ed by mediastinal radiation therapy should be used as a
bypass conduit for the LAD. The use of the radial
artery may be beneficial both for preventing mediasti-
nal wound complications and for avoiding the subopti-
mal use of the ITA as a conduit.26-28
The early result of surgery in this potentially higher
risk group of patients is good, with early mortalities of
8.5% overall and 6.8% in the 44 patients with isolated
CABG. Although preoperative systolic function was
good in the study group, factors present in these
patients that might help explain this increased risk
include a preponderance of women (60%), a high inci-
dence of preoperative left main disease (32%), pul-
monary disease (32%), and carotid disease (23%), and
the increased risk of infection both locally and from
residual generalized immune compromise. The deaths
reflect these special factors in this population. As well
as having an increased early risk, these patients have
compromised late survival because of the occurrence of
a new cancer, recurrence of the previous cancer, and
heart failure, so that 5-year actuarial survival is 72.6%
± 7.1%. Progression of valvular heart disease is a sig-
nificant factor in the subsequent development of heart
failure. Careful follow-up echocardiographic screening
may allow intervention to mitigate progression of
valvular heart disease. 
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Discussion
Dr Bruce W. Lytle (Cleveland, Ohio). This is an important
paper because it highlights radiation-induced heart disease,
which in my judgment is one of the most difficult pathologic
entities that we deal with. Mediastinal radiation causes
numerous problems. Patients with radiation-induced heart
disease may have coronary artery disease or pericardial con-
striction. Most have some type of a restrictive cardiomyopa-
thy with diastolic dysfunction, sometimes in the face of rea-
sonable systolic function. They can have aortic calcification
or calcification of the fibrous skeleton of the heart, causing
aortic stenosis and insufficiency, mitral stenosis and insuffi-
ciency, and tricuspid insufficiency. Cerebrovascular disease is
also prevalent, as well as carotid artery stenosis and pul-
monary fibrosis. 
The authors have focused on a group with a milder form of
radiation-induced heart disease—patients with isolated coro-
nary artery disease without valvular heart disease. Despite
that, this is a high-risk group, with 8.5% of the patients dying.
Of the 40 patients who survived, 17 died late, and of the late
survivors, 10 had class III or class IV symptoms. Further-
more, more than half of the patients who were studied late
had significant valvular heart disease. 
The cardiac injury and mediastinal fibrosis caused by
radiation is progressive. Once a patient has a primary oper-
ation, things get worse before reoperation. If the primary
operation is difficult, reoperations can be an absolute night-
mare once aortic calcification and severe valvular heart dis-
ease have developed. Therefore primary operations for
patients with mediastinal radiation therapy should be very
carefully considered. Obviously, they were in this series,
inasmuch as the patients virtually all had class III or class
IV symptoms and had a high incidence of left main disease.
If there are strong indications for surgery, a careful preop-
erative work-up is needed to define the associated condi-
tions, and moderate valvular lesions need to be treated dur-
ing the first operation. 
I have 2 questions. You excluded the patients with valvular
heart disease from your analysis, but do you have any feeling
about the incremental risk that valvular heart disease carried
with it at the time of those primary operations? 
The second question is a bookkeeping one. The manuscript
lists 40 hospital survivors and 17 late deaths, but the late
functional class data were listed as applying to 39 patients.
How did that all add up? 
Dr Handa. Thank you, Dr Lytle, for your comment. We
currently are evaluating in more detail those patients with
valvular heart disease complicating mediastinal radiation
therapy. Definitive comments today would be premature.
However, 3 patients with moderate mitral valve regurgitation
before the operation and 1 patient with moderate tricuspid
regurgitation who had isolated CABG surgery did not have
valvular lesions at follow-up. 
To clarify the numbers: There were 47 patients in this
study, 4 of whom died, leaving 43 survivors. Among these 43
patients, at a mean follow-up of 6.2 ± 5.1 years, NYHA class
was I in 51% (n = 22), II in 26% (n = 11), III in 14% (n = 6),
and IV in 9% (n = 4).
Dr Hillel Laks (Los Angeles, Calif). I think there are too
few papers addressing this very difficult problem. One of the
challenges that we face in a transplant program is the evalua-
tions of patients such as these, who have poor ventricular
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function, for either CABG or valvular surgery. In general, in
those patients with very low ejection fractions, there seems
also to be a severe diastolic dysfunction of the heart, so that
these patients do not seem to do well with these more con-
ventional types of surgery. In this experience, how many of
the patients had ejection fractions in the 20% or 30% range
and what were the outcomes in that group of patients?
Dr Handa. We agree that diastolic dysfunction is a valid
issue that is difficult to quantitate in these patients. The mean
ejection fraction in this series was 55%. In the overall series
of 47 patients, preoperative ejection fraction was available in
35. Of these 35 patients, 24 had an ejection fraction greater
than 50%, 6 had an ejection fraction of 40% to 50%, 4 had an
ejection fraction of 30% to 40%, and 1 patient had an ejection
fraction of 26%.
Dr Laks. In patients with radiation disease of the posterior
part of the heart and a very low ejection fraction, our bias
would be toward transplantation rather than other forms of
surgery in terms of the short- and long-term outcome. Would
you agree with that? 
Dr Handa. We agree completely with your comments.
Four of our patients with end-stage radiation-induced cardiac
disease have undergone transplantation. In 3 of these patients
the echocardiographic ejection fractions were 15% and in the
fourth, 20%. All patients have done well at a current mean
follow-up of 3 years.
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